Recent advances in nonalcoholic fatty liver disease metabolomics

키워드

참고문헌 (34)

1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
2. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
3. Brunt EM, "NAFLD : reporting histologic findings in clinical practice", Hepatology, 73, pp.2028~2038 (2021)
4. Verhaegh P, "Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis : a systematic review and metaanalysis", Clin Gastroenterol Hepatol, 16, pp.837~861 (2018)
5. Dumas ME, "Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease", Gastroenterology, 146, pp.46~62 (2014)
6. Zhou Y, "Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites", Clin Gastroenterol Hepatol, 14, pp.1463~1472.e6 (2016)
7. Mayo R, "Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis : results from discovery and validation cohorts", Hepatol Commun, 2, pp.807~820 (2018)
8. Barr J, "Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression", J Proteome Res, 11, pp.2521~2532 (2012)
9. Bril F, "Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2diabetes mellitus", Diabetes Obes Metab, 20, pp.1702~1709 (2018)
10. Ekstedt M, "Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
11. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
12. Caussy C, "Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease", Gut, 68, pp.1884~1892 (2019)
13. Caussy C, "Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis", Therap Adv Gastroenterol, 13, pp.1756284820923904~ (2020)
14. Perakakis N, "Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning : a proof of concept study", Metabolism, 101, pp.154005~ (2019)
15. Ogawa Y, "Metabolomic", lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease : a multicenter study, 2020, pp.50, 955~965
16. Kleiner DE, "Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children", Clin Liver Dis, 20, pp.293~312 (2016)
17. Ratziu V, "A critical review of endpoints for non-cirrhotic NASH therapeutic trials", J Hepatol, 68, pp.353~361 (2018)
18. Jung Y, "Circulating lipidomic alterations in obese and non-obese subjects with nonalcoholic fatty liver disease", Aliment Pharmacol Ther, 52, pp.1603~1614 (2020)
19. Yamakado M, "Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors", Sci Rep, 7, pp.14485~ (2017)
20. Gaggini M, "Altered amino acid concentrations in NAFLD : impact of obesity and insulin resistance", Hepatology, 67, pp.145~158 (2018)
21. Hasegawa T, "Changed amino acids in NAFLD and liver fibrosis : a large crosssectional study without influence of insulin resistance", Nutrients, 12, pp.1450~ (2020)
22. Newgard CB, "A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance", Cell Metab, 9, pp.311~326 (2009)
23. Laferrère B, "Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss", Sci Transl Med, 3, pp.80re2~ (2011)
24. Krumsiek J, "Gender-specific pathway differences in the human serum metabolome", Metabolomics, 11, pp.1815~1833 (2015)
25. Grzych G, "Plasma BCAA changes in patients with NAFLD are sex dependent", J Clin Endocrinol Metab, 105, pp.2311~2321 (2020)
26. Masarone M, "Untargeted metabolomics as a diagnostic tool in NAFLD : discrimination of steatosis, steatohepatitis and cirrhosis", Metabolomics, 17, pp.12~ (2021)
27. Haeusler RA, "Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids", Diabetes, 62, pp.4184~4191 (2013)
28. Puri P, "The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids", Hepatology, 67, pp.534~548 (2018)
29. Legry V, "Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects", J Clin Endocrinol Metab, 102, pp.3783~3794 (2017)
30. Nimer N, "Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression", Metabolism, 116, pp.154457~ (2021)
31. Caussy C, "Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD", Aliment Pharmacol Ther, 49, pp.183~193 (2019)
32. Powell EE, "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
33. Nielsen J, "Systems biology of metabolism : a driver for developing personalized and precision medicine", Cell Metab, 25, pp.572~579 (2017)
34. Bjornson E, "Personalized cardiovascular disease prediction and treatment-a review of existing strategies and novel systems medicine tools", Front Physiol, 7, pp.2~ (2016)

관련 논문AI추천